Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 23% ± 8% | |
macrophage | 11 studies | 27% ± 8% | |
microglial cell | 7 studies | 23% ± 7% | |
oligodendrocyte | 7 studies | 25% ± 7% | |
monocyte | 6 studies | 22% ± 4% | |
myeloid cell | 6 studies | 26% ± 5% | |
epithelial cell | 6 studies | 34% ± 13% | |
astrocyte | 6 studies | 30% ± 8% | |
oligodendrocyte precursor cell | 6 studies | 33% ± 9% | |
classical monocyte | 5 studies | 23% ± 5% | |
neuron | 5 studies | 32% ± 18% | |
glutamatergic neuron | 5 studies | 51% ± 18% | |
non-classical monocyte | 4 studies | 23% ± 6% | |
adipocyte | 4 studies | 21% ± 4% | |
fibroblast | 4 studies | 21% ± 5% | |
interneuron | 4 studies | 44% ± 20% | |
hematopoietic precursor cell | 3 studies | 21% ± 5% | |
ciliated cell | 3 studies | 28% ± 9% | |
GABAergic neuron | 3 studies | 50% ± 5% | |
dendritic cell | 3 studies | 27% ± 9% | |
endothelial cell of lymphatic vessel | 3 studies | 20% ± 2% | |
goblet cell | 3 studies | 29% ± 16% | |
hepatocyte | 3 studies | 40% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3536.01 | 1445 / 1445 | 100% | 60.91 | 183 / 183 |
lung | 100% | 3914.45 | 578 / 578 | 100% | 48.14 | 1155 / 1155 |
ovary | 100% | 4281.41 | 180 / 180 | 100% | 42.17 | 430 / 430 |
breast | 100% | 3677.98 | 459 / 459 | 100% | 62.95 | 1116 / 1118 |
prostate | 100% | 3615.11 | 245 / 245 | 100% | 51.24 | 501 / 502 |
uterus | 100% | 4522.34 | 170 / 170 | 100% | 37.93 | 458 / 459 |
intestine | 100% | 3924.06 | 966 / 966 | 100% | 44.50 | 525 / 527 |
bladder | 100% | 3914.29 | 21 / 21 | 100% | 38.15 | 502 / 504 |
stomach | 100% | 2812.72 | 359 / 359 | 99% | 52.00 | 284 / 286 |
liver | 100% | 2972.63 | 226 / 226 | 99% | 31.25 | 403 / 406 |
brain | 99% | 2188.02 | 2621 / 2642 | 100% | 39.71 | 705 / 705 |
thymus | 100% | 3408.72 | 653 / 653 | 99% | 36.93 | 600 / 605 |
kidney | 100% | 2545.69 | 89 / 89 | 99% | 41.39 | 890 / 901 |
adrenal gland | 100% | 4243.26 | 258 / 258 | 98% | 29.35 | 226 / 230 |
pancreas | 99% | 1882.16 | 326 / 328 | 98% | 34.95 | 175 / 178 |
skin | 100% | 4034.81 | 1808 / 1809 | 97% | 52.74 | 456 / 472 |
adipose | 100% | 4092.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3886.98 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 25.48 | 29 / 29 |
muscle | 100% | 4346.74 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3671.46 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 41.52 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.37 | 1 / 1 |
heart | 99% | 2993.38 | 852 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 3191.69 | 888 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 91% | 43.57 | 73 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070925 | Biological process | organelle assembly |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0061157 | Biological process | mRNA destabilization |
GO_0045727 | Biological process | positive regulation of translation |
GO_0045948 | Biological process | positive regulation of translational initiation |
GO_0034063 | Biological process | stress granule assembly |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_1901163 | Biological process | regulation of trophoblast cell migration |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005737 | Cellular component | cytoplasm |
GO_0043022 | Molecular function | ribosome binding |
GO_0005515 | Molecular function | protein binding |
GO_0003729 | Molecular function | mRNA binding |
GO_1990247 | Molecular function | N6-methyladenosine-containing RNA reader activity |
GO_0003723 | Molecular function | RNA binding |
Gene name | YTHDF3 |
Protein name | YTH domain-containing family protein 3 (DF3) YTH N6-methyladenosine RNA binding protein 3 YTH domain-containing family protein |
Synonyms | hCG_41077 |
Description | FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates their stability . M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing . Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex or PAN3 . The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation . Acts as a negative regulator of type I interferon response by down-regulating interferon-stimulated genes (ISGs) expression: acts by binding to FOXO3 mRNAs (By similarity). Binds to FOXO3 mRNAs independently of METTL3-mediated m6A modification (By similarity). Can also act as a regulator of mRNA stability in cooperation with YTHDF2 by binding to m6A-containing mRNA and promoting their degradation . Recognizes and binds m6A-containing circular RNAs (circRNAs); circRNAs are generated through back-splicing of pre-mRNAs, a non-canonical splicing process promoted by dsRNA structures across circularizing exons . Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation . The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules . May also recognize and bind N1-methyladenosine (m1A)-containing mRNAs: inhibits trophoblast invasion by binding to m1A-methylated transcripts of IGF1R, promoting their degradation . .; FUNCTION: Has some antiviral activity against HIV-1 virus: incorporated into HIV-1 particles in a nucleocapsid-dependent manner and reduces viral infectivity in the next cycle of infection . May interfere with this early step of the viral life cycle by binding to N6-methyladenosine (m6A) modified sites on the HIV-1 RNA genome . . FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates mRNA stability. M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing. . FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates mRNA stability. M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing. . FUNCTION: Specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, and regulates mRNA stability. M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing. . |
Accessions | ENST00000612880.4 ENST00000517371.5 A0A087X0C3 A0A087WY31 A0A087WU40 A0A087X0U5 ENST00000539294.6 ENST00000623280.3 A0A087WU63 ENST00000621413.4 ENST00000617952.4 A0A087X0Q1 ENST00000613853.4 Q7Z739 ENST00000617200.1 A0A087WWB0 ENST00000619337.4 ENST00000621957.4 A0A024R7W5 ENST00000615676.1 ENST00000621820.4 ENST00000621890.4 S4R373 |